共 91 条
[11]
Goadsby PJ(2022)Cardiovascular disease and migraine: are the new treatments safe? Curr Pain Headache Rep 26 647-655
[12]
Dodick DW(2020)Migraine, obesity and body fat distribution—a population-based study J Headache Pain 21 97-211
[13]
Ailani J(2023)Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial Cephalalgia 43 3331024221128250-785
[14]
Trugman JM(2018)The International Classification of Headache Disorders, 3rd edition Cephalalgia 38 1-11
[15]
Finnegan M(2023)Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 402 775-350
[16]
Lu K(2022)Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial Cephalalgia 42 3-1808
[17]
Ailani J(2021)Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials J Headache Pain 22 16-undefined
[18]
Lipton RB(2022)Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials J Headache Pain 23 104-undefined
[19]
Goadsby PJ(2018)CGRP as the target of new migraine therapies - successful translation from bench to clinic Nat Rev Neurol 14 338-undefined
[20]
Guo H(2022)Post-hoc analysis evaluating safety of atogepant in ADVANCE & open-label extension participants with cardiovascular risk factors [abstract P-137] Headache 62 119-undefined